Screening for glaucoma in adults : systematic review for the U.S. Preventive Services Task Force

Screening for glaucoma in adults systematic review for the U.S. Preventive Services Task Force

BACKGROUND: In 2013, the United States Preventive Services Task Force (USPSTF) concluded that the evidence was insufficient to assess the balance of benefits and harms of screening for primary open angle glaucoma in adults (I Statement). Although the USPSTF found that treatment of increased intraocu...

Descripción completa

Detalles Bibliográficos
Otros Autores: Chou, Roger, author (author)
Formato: Libro electrónico
Idioma:Inglés
Publicado: Rockville, MD : Agency for Healthcare Research and Quality 2022.
Colección:Evidence syntheses.
Materias:
Glaucoma > Diagnosis.
Ver en Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820265006719
Tabla de Contenidos:
  • Acknowledgments
  • Chapter 1. Introduction and Background
  • Purpose
  • Condition Background
  • Chapter 2. Methods
  • Key Questions and Analytic Framework
  • Search Strategies
  • Study Selection
  • Data Abstraction and Quality Rating
  • Data Synthesis and Analysis
  • USPSTF and AHRQ Involvement
  • Expert Review and Public Comment
  • Chapter 3. Results
  • Key Question 1. What Are the Effects of Screening for OAG vs. No Screening on a IOP, Visual Field Loss, Visual Acuity, or Optic Nerve Damage or b Visual Impairment, Quality of Life, or Function?
  • Key Question 2. What Are the Harms of Screening for OAG vs. No Screening?
  • Key Question 3. What Are the Effects of Referral to an Eye Health Provider vs. No Referral on a IOP, Visual Field Loss, Visual Acuity, or Optic Nerve Damage or b. Visual Impairment, Quality Of Life, or Function?
  • Key Question 4. What Is the Accuracy of Screening for Diagnosis of OAG?
  • Key Question 5. What Is the Accuracy of Instruments for Identifying Patients at Higher Risk of OAG?
  • Key Question 6. What Are the Effects of Medical Treatments for OAG vs. Placebo or No Treatments on a. IOP, Visual Field Loss, Visual Acuity, or Optic Nerve Damage or b. Visual Impairment, Quality of Life, or Function?
  • Key Question 7. What Are the Harms of Medical Treatments for OAG vs. Placebo or No Treatments?
  • Key Question 8. What Are the Effects of Newly FDA-Approved Medical Treatments (Latanoprostene Bunod and Netarsudil) vs. Older Medical Treatments on a. IOP, Visual Field Loss, Visual Acuity, or Optic Nerve Damage or b. Visual Impairment, Quality of Life, or Function?
  • Key Question 9. What Are the Harms of Newly FDA-Approved Medical Treatments vs. Older Medical Treatments?
  • Key Question 10. What Are the Effects of Laser Trabeculoplasty for OAG vs. No Trabeculoplasty or Medical Treatment on a. IOP, Visual Field Loss, Visual Acuity, or Optic Nerve Damage or b. Visual Impairment, Quality of Life, or Function?
  • Key Question 11. What Are the Harms of Laser Trabeculoplasty for OAG vs. No Trabeculoplasty or Medical Treatment?
  • Contextual Question 1. What Is the Association Between Changes in IOP, Visual Field Loss, Visual Acuity, or Optic Nerve Damage Following Treatment for OAG and Improvement in Visual Impairment, Quality of Life, or Function, and What Is the Association Between Changes in IOP and Visual Field Loss?
  • Chapter 4. Discussion
  • Summary of Review Findings
  • Limitations
  • Emerging Issues/Next Steps
  • Relevance for Priority Populations
  • Future Research
  • Conclusions
  • References
  • Appendixes
  • Appendix A. Detailed Methods
  • Appendix B. Evidence Tables and Quality Tables.

Ejemplares similares